Adicet bio to present at the virtual jmp securities hematology and oncology summit

Redwood city, calif. & boston--( business wire )--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for cancer, today announced that chen schor, president and chief executive officer, will present at the virtual jmp securities hematology and oncology summit being held from december 6-7, 2022.
ACET Ratings Summary
ACET Quant Ranking